Eliem Therapeutics Inc (ELYM)
7.59
-0.07
(-0.91%)
USD |
NASDAQ |
May 31, 16:00
7.68
+0.09
(+1.19%)
Pre-Market: 20:00
Eliem Therapeutics Research and Development Expense (Annual): 15.41M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 15.41M |
| December 31, 2022 | 26.21M |
| December 31, 2021 | 23.32M |
| Date | Value |
|---|---|
| December 31, 2020 | 9.342M |
| December 31, 2019 | 4.019M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
4.019M
Minimum
2019
26.21M
Maximum
2022
15.66M
Average
15.41M
Median
2023
Research and Development Expense (Annual) Benchmarks
| Alpine Immune Sciences Inc (DELISTED) | 80.90M |
| Candel Therapeutics Inc | 24.51M |
| Cyclacel Pharmaceuticals Inc | 19.16M |
| Lipocine Inc | -- |
| GlycoMimetics Inc | 20.07M |